TBTomer Babu

Tomer Babu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomer Babu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures

    by Tomer Babu, Matthew S. Levine, Bingsong Zeng, Jonathan L. Sessler

    A next-generation Pt( iv )–Au( i ) multimetal complex incorporating gemcitabine enhances cytotoxicity and ICD. RNA-seq pathway analysis reveals transcriptomic signatures predictive of ICD potential (created in BioRender, T. Babu).


  • Open Access

    Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death

    by Tomer Babu, Matthew S. Levine, Sourav Acharya, Esther Y. Maier, Jonathan L. Sessler

    Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.


  • Open Access

    Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death

    by Tomer Babu, Matthew S. Levine, Sourav Acharya, Esther Y. Maier, Jonathan L. Sessler

    Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.


  • Open Access

    Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy

    by Vojtech Novohradsky, Tomer Babu, Hana Kostrhunova, Menucha Plaskow, Lenka Markova, Sourav Acharya, Dan Gibson, Viktor Brabec


  • Open Access

    Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain

    by Tomer Babu, Ram Pravin Kumar Muthuramalingam, Wei Heng Chng, Jia Ning Nicolette Yau, Sourav Acharya, Nurit Engelmayer, Rachel Feldman-Goriachnik, Shaya Lev, Giorgia Pastorin, Alexander Binshtok, et al.

    Cisplatin and oxaliplatin are Pt(II) anticancer agents that are used to treat several cancers, usually in combination with other drugs. Their efficacy is diminished by dose-limiting peripheral neuropathy (PN) that affects ∼70% of patients. PN is caused by selective accumulation of the platinum drugs in the dorsal root ganglia (DRG), which overexpress transporters for cisplatin and oxaliplatin. To date, no drug is recommended for the prevention of PN. We report that Pt(IV) prodrugs of cisplatin or oxaliplatin do not induce neuropathic pain in mice, likely due to the lower accumulation of platinum in the DRG compared with Pt(II) drugs. Moreover, the multitargeting prodrug that combines cisplatin with paclitaxel, both strong inducers of PN, efficiently inhibited tumor growth in vivo without inducing neuropathic pain. The high antitumor efficacy of Pt(IV) prodrugs and their micellar counterparts and the low level of neuropathic pain associated with them make them ideal candidates for clinical use in cancer therapy.


  • Open Access

    Stepwise optimization of tumor-targeted dual-action platinum( iv )-gemcitabine prodrugs

    by Alexander Kastner, Theresa Mendrina, Tomer Babu, Subhendu Karmakar, Isabella Poetsch, Walter Berger, Bernhard K. Keppler, Dan Gibson, Petra Heffeter, Christian R. Kowol

    An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.


  • Open Access

    Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death

    by Amrita Sarkar, Vojtech Novohradsky, Moumita Maji, Tomer Babu, Lenka Markova, Hana Kostrhunova, Jana Kasparkova, Valentina Gandin, Viktor Brabec, Dan Gibson

    A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.


  • Open Access

    Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death

    by Amrita Sarkar, Vojtech Novohradsky, Moumita Maji, Tomer Babu, Lenka Markova, Hana Kostrhunova, Jana Kasparkova, Valentina Gandin, Viktor Brabec, Dan Gibson

    A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.


  • Open Access

    Oral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity

    by Tomer Babu, Hiba Ghareeb, Uttara Basu, Hemma Schueffl, Sarah Theiner, Petra Heffeter, Gunda Koellensperger, Norman Metanis, Valentina Gandin, Ingo Ott, et al.

    AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.


  • Open Access

    Oral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity

    by Tomer Babu, Hiba Ghareeb, Uttara Basu, Hemma Schueffl, Sarah Theiner, Petra Heffeter, Gunda Koellensperger, Norman Metanis, Valentina Gandin, Ingo Ott, et al.

    AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.